ADMA Gains 13.8% in Three Months: More Upside Potential for 2026?

Key Takeaways ADMA stock gained 13.8% in three months, beating the industry, sector, and the S&P 500 over the period.ADMA is seeing accelerating Asceniv use from prescriber adoption, payer access and supply confidence.ADMA raised 2026 revenue and EBITDA targets as yield-enhanced production lift margins.ADMA Biologics’ (ADMA) shares have gained 13.8% in the past three months compared with the industry’s growth of 9%. The stock has outperformed the sector and the S&P 500 in this timeframe.The rebound has been ...